Company: ENTXW
Filing Date: 2025-06-06
Form Type: 424B3
Source: 0001178913-25-002133
Chunk: 3

Company: Entera Bio Ltd.
Filing Date: 2025-06-06
Form: 424B3
Chunk 3
---
 the first and only GLP-2 peptide tablet alternative for patients suffering from short bowel syndrome and additional disorders involving mucosal inflammation and nutrient malabsorption. OXM is a naturally occurring peptide hormone found in the colon, with glucagon-like-peptide 1 (GLP-1) and glucagon dual agonist activity that suppresses appetite and induces weight loss. In September 2024, we jointly announced with OPKO topline pharmacokinetic/pharmacodynamic (PK/PD) results for the OXM program. The program is focused on developing the first oral dual agonist GLP-1/Glucagon peptide as a potential once-daily tablet treatment for patients with obesity and metabolic disorders using the N-Tab™ platform. In March 2025, we entered into an additional collaboration and license agreement with OPKO with respect to the preclinical and clinical development and decision making related to the oral OXM program for the treatment of obesity, metabolic and fibrotic disorders in humans. Given the scarcity of oral peptide treatments and potential safety challenges attributed to small molecule approaches, we believe oral OXM may address a significant number of patients suffering from chronic metabolic diseases. Corporate Information Our principal and registered office is located at Kiryat Hadassah Minrav Building - Fifth Floor, Jerusalem, Israel, and our telephone number is +972-2-532-7151. Our corporate website is located at www.enterabio.com. The information on our website shall not be deemed part of this prospectus. S-2

THE OFFERING

| Ordinary Shares Offered by Us                        | Up to 30,000,000 ordinary shares.                                                                                                                                                                                                  |
| Ordinary Shares to be Outstanding after thisOffering | Up to 75,452,167 ordinary shares assuming sales of 30,000,000 ordinary shares. The Company is not obligated to issue and sell any minimum number of shares under this offering.                                                    |
| Plan of Distribution                                 | Sales of ordinary shares, if any, will be made from time to time in sales deemed to be an “at the market offering” as defined in Rule 415 promulgated under the Securities Act. Leerink                                            
 Partners will act as agent or principal and will use reasonable best efforts to sell on our behalf all of the ordinary shares requested to be sold by us, consistent with its normal trading and sales practices. See “Plan of     
 Distribution.”                                                                                                                                                                                                                     |
| Use of Proceeds                                      | We intend to use the net proceeds from this offering, if any, primarily